Drugs / Fuzheng Huayu Tablets
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 42 trials | ||||||
| Phase 4 | NCT07663643 | May 2026 → Oct 2027 expected | metabolic dysfunction-associated steatotic liver disease | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT00543426 | Sep 2007 → May 2009 | cirrhosis of liver | Shanghai University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07017426 | Jul 2025 → Jul 2027 expected | cirrhosis of liver | Zhiyun Yang | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fuzheng Huayu Tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00543426 ↗ |
| Known as | Fuzheng Huayu tablet | “Fuzheng Huayu tablet is used as a classic anti-hepatic fibrosis herbal compound.” PMID 42465987 ↗ Jul 2026 |
| Modality | Traditional medicine (herbal / TCM) | “Fuzheng Huayu tablet is used as a classic anti-hepatic fibrosis herbal compound.” PMID 42465987 ↗ Jul 2026 |
| Route | Oral | “Fuzheng Huayu Tablets, 4 tablets each time, 3 times daily, orally administered.” NCT07663643 ↗ |